147 related articles for article (PubMed ID: 17713475)
1. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
[TBL] [Abstract][Full Text] [Related]
2. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
4. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
[TBL] [Abstract][Full Text] [Related]
6. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not.
Sombogaard F; Peeters AM; Baan CC; Mathot RA; Quaedackers ME; Vulto AG; Weimar W; van Gelder T
Ther Drug Monit; 2009 Oct; 31(5):549-56. PubMed ID: 19704402
[TBL] [Abstract][Full Text] [Related]
7. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
8. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
[TBL] [Abstract][Full Text] [Related]
10. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation.
Glander P; Hambach P; Braun KP; Fritsche L; Giessing M; Mai I; Einecke G; Waiser J; Neumayer HH; Budde K
Am J Transplant; 2004 Dec; 4(12):2045-51. PubMed ID: 15575908
[TBL] [Abstract][Full Text] [Related]
12. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
13. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic monitoring of mycophenolate mofetil.
Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
[TBL] [Abstract][Full Text] [Related]
15. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
[TBL] [Abstract][Full Text] [Related]
16. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
[TBL] [Abstract][Full Text] [Related]
17. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.
Sombogaard F; van Schaik RH; Mathot RA; Budde K; van der Werf M; Vulto AG; Weimar W; Glander P; Essioux L; van Gelder T
Pharmacogenet Genomics; 2009 Aug; 19(8):626-34. PubMed ID: 19617864
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
19. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil--clinical and experimental experience.
Pirsch JD; Sollinger HW
Ther Drug Monit; 1996 Aug; 18(4):357-61. PubMed ID: 8857550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
